ClinicalTrials.gg
CompletedNCT01034202Updated Feb 9, 2017

Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

A Phase 1 interventional study of NNC126-0083 and Norditropin® SimpleXx® in Growth Hormone Disorder and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Denmark. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-09.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NNC126-0083 compared to Norditropin® SimpleXx® and placebo in healthy volunteers

02

Conditions studied

  • Growth Hormone Disorder
  • Healthy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, non-smoking male subjects
  • (BMI) between 19.0 and 28.0 kg/m2, both inclusive
  • Body weight max. 100 kg

Exclusion criteria

Exclusion Criteria:

  • A history or presence of cancer, diabetes, or any cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, psychiatric diseases or other major diseases
  • Carrier of surface antigen (HBsAg) or antibodies
  • Positive result of test for (Human Immunodeficiency Virus) antibodies
  • Any clinically significant abnormal haematology or biochemistry screening tests, as judged by the physician
  • Clinically significant abnormal (ElectroCardioGram) at screening as evaluated by the physician
  • A significant history of alcoholism or drug/chemical abuse, or who has a positive result in the urine drug/alcohol screen, or who consumes more than 28 units of alcohol per week (one unit of alcohol equals about 250 ml of beer or lager, 1 glass of wine, or 20 ml of spirits)
  • Habitual smoking, i.e daily smoking or more than 7 cigarettes/week
  • Mental incapacity or language barriers which preclude adequate understanding or cooperation, who are unwilling to participate in the trial, or who in the opinion of their general practitioner or the Investigator should not participate in the trial
  • Surgery or trauma with significant blood loss within the last 2 months prior to dosing
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083

    Drug: NNC126-0083 · Drug: Norditropin® SimpleXx®

  • Experimental
    Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083

    Drug: NNC126-0083 · Drug: Norditropin® SimpleXx®

  • Placebo comparator
    Norditropin® SimpleXx® 0.02 mg/kg + placebo

    Drug: placebo · Drug: Norditropin® SimpleXx®

  • Placebo comparator
    Norditropin® SimpleXx® 0.04 mg/kg + placebo

    Drug: placebo · Drug: Norditropin® SimpleXx®

  • Experimental
    NNC126-0083

    Drug: NNC126-0083

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • One of five dose levels administered subcutaneously (under the skin)

  • One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)

  • Drugplacebo

    Placebo comparator

  • One of three dose levels administered subcutaneously (under the skin)

  • One of two dose levels, followed by placebo, administered subcutaneously (under the skin)

06

What researchers measure

Primary outcomes

  1. Number of adverse events

    Time frame: after administration of a single dose of NNC126-0083

Secondary outcomes

  1. Area under the curve (AUC) (0-168h) after a single dose of NNC 126-0083

    Time frame: 0-168 hours after trial drug administration

  2. Number of injection site reactions

    Time frame: after administration of a single dose of NNC126-0083 and after single dose of Norditropin® SimpleXx®

  3. IGF-I (Insulin-like Growth Factor I) levels

    Time frame: after ascending single doses of NNC126-0083 and a single dose of Norditropin® SimpleXx®

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Hvidovre, 2650, Denmark
08

References and documents

Publications

  • Rasmussen MH, Bysted BV, Anderson TW, Klitgaard T, Madsen J. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile. J Clin Endocrinol Metab. 2010 Jul;95(7):3411-7. doi: 10.1210/jc.2009-2813. Epub 2010 Apr 28. PubMed 20427496 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2009
First posted
Dec 17, 2009
Start
Aug 2007
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Last update
Feb 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01034202
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 17, 2009
Start date
Aug 2007
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Feb 9, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Somatropin pegol · Human Growth Hormone

Start the discussion